RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Clinical trial NCT07065435 · RECRUITING
Trial details
- NCT number
- NCT07065435
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-01
- Primary completion
- 2025-12-01
- Enrollment
- 74
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.